Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell Malignancies

Inclusion Criteria: 1. Diagnosed with relapsed and refractory CD7 + T cell hematologic malignancies (including, but not limited to, T-cell leukemia, extranodal NK/ T-cell lymphoma nasal, peripheral T-cell lymphoma, enteropathy associated T-cell lymphoma and anaplastic T-cell lymphoma, etc.); 2. No alternative treatment options deemed by investigator; 3. Measurable or detectble disease at time of enrollment; 4. Age 18-70 years old, no gender and race limited; 5. Eastern cooperative oncology group (ECOG) performance status of ≤2; 6. Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO); 7. Estimated life expectancy \> 12 weeks deemed by investigator; 8. Serum creatinine ≤ 1.5 upper limit of normal (ULN); 9. Serum ALT/ AST ≤ 5 upper limit of normal (ULN); 10. Signed informed consent form (ICF). Exclusion Criteria: 1. Women in pregnancy or lactation; 2. Uncontrolled infection; 3. Active hepatitis B virus or hepatitis C virus infection; 4. Concurrent use of corticosteroids or other immunosuppressant medications for chronic disease; 5. Prior treatment with an allogeneic stem cell transplant within 100 days; 6. Grade 2-4 Active graft versus host disease; 7. History of HIV infection; 8. With central nervous system involvement; 9. Patients combine with other disease cause neutrophil count (ANC) \< 750/uL or PLT\< 50,000/uL.